Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | DTYMK | P23919 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 5/20 | 0.34 |
| ▸ | JAK1 | P23458 | 5/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.32 |
| ▸ | CCNK | O75909 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCND3 | P30281 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10125429 | 0.82 | POLB (0.41) | POLBGPR119DTYMKJAK2JAK1 | |
| SCHEMBL15033820 | 0.80 | POLB (0.40) | POLBGPR119DTYMKJAK2JAK1 | |
| SCHEMBL10125376 | 0.78 | PTK2 (0.44) | JAK2CDK2CDK9 | |
| SCHEMBL10125419 | 0.76 | POLB (0.43) | POLBGPR119DTYMKJAK2JAK1 | |
| SCHEMBL2899250 | 0.76 | GRM5 (0.43) | POLBGPR119DTYMKJAK2JAK1 | |
| SCHEMBL10125364 | 0.74 | GPR119 (0.42) | POLBGPR119DTYMKJAK2JAK1 | |
| SCHEMBL15033814 | 0.72 | GRM5 (0.40) | POLBGPR119DTYMKJAK2JAK1 | |
| SCHEMBL3886709 | 0.70 | GPR119 (0.46) | POLBGPR119DTYMKJAK2JAK1 | |
| SCHEMBL3555626 | 0.68 | POLB (0.48) | POLBGPR119DTYMKJAK2JAK1 | |
| SCHEMBL31227168 | 0.67 | POLB (0.50) | POLBGPR119ACHECCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606034-B1 | PYRIMIDINE DERIVATIVE AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-8906916-B2 | Pyrimidine derivatives as FAK inhibitors | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8906916-B2 | Pyrimidine derivatives as FAK inhibitors | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-20 | — | — | US | disclosed |
| WO-2012022408-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158005-A1 | PYRIMIDINE DERIVATIVES AS FAK INHIBITORS | CDK2, PTK2, CDKN1A | POLB 723/4885GPR119 1536/4885DTYMK 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.